Is a Functional Cure for Multiple Myeloma Within Reach?

For decades, the conversation surrounding multiple myeloma was defined by a difficult truth: The disease was considered treatable, but not curable. However, according to experts who spoke with CURE, that narrative is shifting. We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

A decade of revolution

"The landscape of myeloma treatment truly went through a revolution in the past 10 years," said Dr. Natalia Neparidze of the Yale School of Medicine. In oncology, a traditional "cure" is defined as being therapy-free and cancer-free for at least five years. Although myeloma hasn't historically fit this mold, new data are challenging the status quo.

Neparidze points to landmark chimeric antigen receptor T-cell therapy (CAR-T) trials, such as CARTITUDE-4 and KarMMa, where about one-third of patients remain progression-free three to five years after a single intervention. For these patients, the dream of a long-term reprieve from cancer is becoming a reality.

Defining the ‘functional cure’

Not every patient has immediate access to CAR-T cell therapy, but the goal of a functional cure remains inclusive. For those who stay on ongoing therapies, the goal is to transform myeloma from an active, aggressive cancer into a manageable chronic illness.

"I think that’s pretty close to what you would expect with other chronic diseases like diabetes or congestive heart failure," Neparidze explained. If a patient can maintain a high quality of life with once-a-month treatments for years, the disease is effectively sidelined.

The power of T-cell fitness

Dr. Prerna Mewawalla of Allegheny Health Network emphasizes that the timing of these advanced treatments matters. Early data from the CARTITUDE-1 study showed an overall survival of five years in patients who had already failed four or more lines of treatment.

Now, CAR-T is moving into earlier lines of care. "We have patients who are less refractory; they have better T-cell fitness going into it," said Mewawalla. By treating the disease before it becomes highly resistant, doctors expect even better long-term outcomes.

Overcoming the remaining barriers

Despite the optimism, the path is not without obstacles. Mewawalla highlighted several "unmet needs," including the following:

• Access: Many patients live too far from specialized centers capable of delivering CAR-T.
• Manufacturing Time: The "vein-to-vein" time (the weeks it takes to engineer a patient's cells) can be too long for those with ultra-high-risk disease.
• Toxicity: Although rare, long-term neurotoxicities remain a concern that researchers are working to minimize with newer generations of T-cell therapies.

Better potency, better detection

To claim a cure, you have to be able to prove the cancer is gone. Dr. Ajai Chari of the University of California San Francisco noted that we now have the "amazing therapies" and the "sophisticated technology" to do just that.

The medical community is now utilizing minimal residual disease testing, which can detect a single cancer cell among a million healthy ones. With today’s high-sensitivity testing and mass spectrometry of the blood, doctors finally have the fine-tuned scale needed to challenge themselves and the disease to define a true cure.

For the first time in history, the myeloma community isn't just hoping for more time; they are defining what it means to be cured.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.